The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More
Author Archives: admin
LODESTAR Trial: Statin and CAD
The LODESTAR trial, as featured in JAMA in 2023, was a randomized, multicenter, noninferiority trial focusing on coronary artery disease (CAD) treatment strategies. The objective was to assess whether a treat-to-target strategy for low-density lipoprotein cholesterol (LDL-C) is noninferior to … Read More
HEART-FID Trial: Iron in Heart Failure
The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More
FIRE Trial: Complete PCI in MI in Older Patients
The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More
ECLS-SHOCK Trial: Extracorporeal Life Support in Cardiogenic Shock
The ECLS-SHOCK trial, as reported in the New England Journal of Medicine in 2023, was a multicenter, parallel, randomized controlled trial designed to evaluate the efficacy of extracorporeal life support (ECLS) in patients with acute myocardial infarction (MI) complicated by … Read More
ACTIV-6 Trial: Inhaled Fluticasone in Covid-19
The ACTIV-6 trial, published in the New England Journal of Medicine in 2023, examines the effectiveness of inhaled fluticasone furoate in the treatment of non-hospitalized patients with mild to moderate COVID-19. The trial was a decentralized, double-blind, randomized, placebo-controlled study … Read More
SURPASS-6 Trial: Tirzepatide in T2DM
The SURPASS-6 trial, featured in JAMA in October 2023, represents a significant advancement in the treatment of type 2 diabetes. This randomized, phase 3, open-label trial was designed to evaluate the effects of once-weekly subcutaneous (SC) tirzepatide versus thrice-daily prandial … Read More
EMERGE Trial: Metformin in Gestational Diabetes
The EMERGE trial, published in JAMA in October 2023, is a pivotal study in the field of obstetric care, specifically targeting the management of gestational diabetes—a condition of elevated blood sugar that occurs during pregnancy. The trial’s goal was to … Read More
ESCAPE-TRD Trial: Esketamine in Depression
The ESCAPE-TRD trial, as reported in the New England Journal of Medicine in 2023, stands as a significant landmark in the ongoing quest to improve treatments for treatment-resistant depression (TRD). This trial assessed the efficacy and safety of esketamine nasal … Read More
RADIANCE-HTN TRIO Trial: Renal Denervation in HTN
The RADIANCE-HTN TRIO trial, detailed in The Lancet in 2021, is another pivotal study in the domain of hypertension treatment, focusing on a challenging group of patients: those resistant to a standard triple combination pill. This trial delves into the … Read More